


Ask a doctor about a prescription for VENORUTON OXERUTINES 1 g ORAL SOLUTION POWDER
Package Leaflet: Information for the User
Venoruton Oxerutins 1 g Powder for Oral Solution
Oxerutins
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist.
Siga exactamente las instrucciones de administración del medicamento contenidas en este prospecto o las indicadas por su médico o farmacéutico.
Should consult a doctor if it worsens or does not improve after 1 or 2 weeks, depending on the indication.
Contents of the Package Leaflet:
The active ingredient of Venoruton Oxerutins is oxerutins, which belongs to the group of vasoprotective medications, which protect blood vessels (systemic vasoprotectors).
It is indicated, in adults, for the relief of symptoms related to mild venous insufficiency of the lower limbs, such as pain, feeling of heaviness, tightness, tingling, and itching in legs with varices or swollen legs.
It is indicated for the relief of symptoms related to hemorrhoids, such as pain or inflammation in the anal area, in adults.
Should consult a doctor if it worsens or does not improve after 2 weeks of treatment in case of venous insufficiency, or after 1 week of treatment in case of hemorrhoids.
Do not take Venoruton Oxerutins:
Warnings and precautions
Children and adolescents
Venoruton Oxerutins is not intended for use in children and adolescents (under 18 years of age).
Taking Venoruton Oxerutins with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Taking Venoruton Oxerutins with food, beverages, and alcohol
Taking this medication with food or beverages does not affect its efficacy.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
According to generally accepted safety recommendations, Venoruton Oxerutins should not be used during the first 3 months of pregnancy.
It is not known whether the medication passes into breast milk, so its use is not recommended during breastfeeding.
Driving and using machines
You may experience fatigue and dizziness when using Venoruton Oxerutins, although this is rare. If this happens, do not drive or operate machinery.
Venoruton Oxerutins contains sucrose and sodium
This medication contains sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free”.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor, pharmacist, or nurse. If in doubt, ask your doctor, pharmacist, or nurse.
Adults:
Venous insufficiency:
The recommended dose is 1 sachet per day.
Relief of symptoms usually occurs within the first 2 weeks of treatment.
If you do not feel relief after 2 weeks or symptoms worsen, you should consult your doctor.
On medical indication, treatment can be continued with the same daily dose (1 sachet) for up to 2-3 months.
Hemorrhoids:
The recommended dose is 1 sachet per day. If symptoms do not improve or worsen within the first week of treatment, you should consult your doctor.
Method of administration
To open, please separate the sachets at the perforated zone. Open each sachet individually by tearing the sachet from the indicated point by the arrow; if you cannot open the sachet with your hands, you can use scissors.
Dissolve the contents of the sachet in 1 glass of water and drink immediately.
If you take more Venoruton Oxerutins than you should
In case of accidental ingestion, consult your doctor or pharmacist, or call the Toxicological Information Service. Phone 91 562 04 20.
If you forget to take Venoruton Oxerutins
Do not take a double dose to make up for forgotten doses.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
If you interrupt treatment with Venoruton Oxerutins
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication can cause side effects, although not everyone will experience them.
If you experience any of these symptoms, which may be signs of an allergic/anaphylactic reaction, stop treatment and consult a doctor immediately:
Rare side effects: may affect up to 1 in 1,000 patients
Gastrointestinal disorder, flatulence, diarrhea, abdominal pain, stomach discomfort, dyspepsia, rash, itching, or urticaria.
Very rare side effects: may affect up to 1 in 10,000 patients
Allergic reactions
Dizziness, headache, fatigue, skin redness.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use. Website: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the box after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture. Store below 30°C.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Venoruton Oxerutins
Each sachet contains 1 g of oxerutins
Appearance and packaging of the product
Pale yellow powder.
Venoruton powder for oral solution is presented in packs of 14, 28, or 30 sachets of PET/PE/Aluminum 12 µm/Surlyn complex.
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratory STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
SmithKline Beecham, S.A.
Ctra. de Ajalvir, Km. 2,500
Alcalá de Henares, 28806
Madrid, Spain
Or
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Date of the last revision of this package leaflet: May 2025
Other sources of information
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for VENORUTON OXERUTINES 1 g ORAL SOLUTION POWDER – subject to medical assessment and local rules.